A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study to Evaluate The Efficacy And Safety of Rivipansel (GMI-1070) in The Treatment of Vaso-Occlusive Crisis in HospitalizedSubjects with Sickle Cell Disease
A study for patients with Sickle Cell Disease using study drug Rivipansel
Sponsor: Pfizer
Enrolling: Male and Female Patients
IRB Number: AAAQ2308
U.S. Govt. ID: NCT02187003
Contact: Margaret Lee, MD: 212-305-9770 / ml653@cumc.columbia.edu
Additional Study Information: This study is for patients with sickle cell disease (SCD). SCD is an inherited genetic disorder in which red blood cells become abnormally shaped (sickle cells). These sickle cells may block blood vessels and result in a vaso occlusive crisis (VOC). This leads to inflammation and tissue damage and causes pain in various parts of the body. The purpose of this current research study is to compare the study drug, rivipansel, with a placebo in a larger number of subjects to find out if rivipansel is safe and effective for treating pain crisis in hospitalized subjects with SCD. Researchers use a placebo to see if the study drug works better than not taking anything and to compare the safety of the study drug with not taking anything.
This study is closed
Margaret Lee, MD
Do You Qualify?
Have you or your child been diagnosed with sickle cell disease? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Margaret Lee, MD